Drug Trial Radar · NCT07436949
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Bambusa TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, double-Blind, placebo-controlled, Single and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with or without Asthma.
Conditions
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
BBT002Drug
BBT002 will be administered.
PlaceboDrug
Placebo will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events following single and multiple administration of BBT002Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in vital sign measurements following dose administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in physical examination following dose administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in Laboratory assessmentsTime frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in 12-lead ECG readingsTime frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
People's Hospital of Peking University
Beijing, Beijing Municipality, China · Recruiting
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
The Second Hospital of Shandong Province
Jinan, Shandong, China · Recruiting
Qingdao University Hospital
Qingdao, Shandong, China · Recruiting
The Affiliated Yuhuangding Hospital of Qingdao University
Yantai, Shandong, China · Recruiting
Zibo Hospital of Shandong University
Zibo, Shandong, China · Recruiting
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
The Second Hospital of Chengdu City
Chengdu, Sichuang, China · Recruiting
Zhejiang People's Hospital
Hangzhou, Zhejiang, China · Recruiting
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.